Publications
Detailed Information
Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hak Jae | - |
dc.contributor.author | Ha, Sung Whan | - |
dc.contributor.author | Wu, Hong-Gyun | - |
dc.date.accessioned | 2012-06-15T05:43:14Z | - |
dc.date.available | 2012-06-15T05:43:14Z | - |
dc.date.issued | 2009-12 | - |
dc.identifier.citation | JOURNAL OF GYNECOLOGIC ONCOLOGY; Vol.20 4; 227-231 | ko_KR |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77104 | - |
dc.description.abstract | Objective: To evaluate treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy (POEFRT) with or without chemotherapy. Methods: Between 1983 and 2006, 35 patients with a pathologically confirmed positive para-aortic node (PAN) or common iliac node (CIN) who underwent a radical hysterectomy with bilateral pelvic lymph node dissection and PAN dissection received POEFRT with (N=23) or without (N=12) chemotherapy. Prognostic factors such as age, stage, size, parametrium invasion, lymphovascular space invasion, nodal station, depth of stromal invasion and use of chemotherapy were analyzed. Results: With a median follow-up of 44 months, the 5-year overall survival (OS), disease-free survival (DFS), distant failure-free survival (DFFS) and loco-regional failure-free survival rates were 51%, 51%, 59% and 93%, respectively. The use of chemotherapy significantly improved the 5-year OS rate (61% vs. 48%, p=0.004), the 5-year DFS rate (54% vs. 38%, p=0.004) and the 5-year DFFS rate (57% vs. 48%, p=0.009). PAN involvement resulted in a compromised 5-year DFS rate (42% vs. 73%, p=0.002) and 5-year DFFS rate (47% vs. 82%, p=0.004) as compared to CIN involvement. Grade 3 or higher hematological toxicity was observed more frequently in patients who received POEFRT combined with chemotherapy as compared to patients who received POEFRT alone (52% vs. 17%, p=0.04). Conclusion: The use of POEFRT resulted in an excellent loco-regional control rate. The addition of chemotherapy may improve outcome in patients who have received POEFRT, but with higher manageable toxicity. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY | ko_KR |
dc.subject | Cervix cancer | ko_KR |
dc.subject | Postoperative extended field radiotherapy | ko_KR |
dc.subject | Chemotherapy | ko_KR |
dc.title | Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김학재 | - |
dc.contributor.AlternativeAuthor | 하성환 | - |
dc.contributor.AlternativeAuthor | 우홍균 | - |
dc.identifier.doi | 10.3802/jgo.2009.20.4.227 | - |
dc.citation.journaltitle | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.description.citedreference | PETEREIT DG, 2007, CLIN RAD ONCOLOGY, P1323 | - |
dc.description.citedreference | Kim K, 2006, GYNECOL ONCOL, V101, P398, DOI 10.1016/j.ygyno.2005.10.035 | - |
dc.description.citedreference | STEHMAN FB, 2005, PRINCIPLES PRACTICE, P761 | - |
dc.description.citedreference | Saad A, 2004, AM J CLIN ONCOL-CANC, V27, P256, DOI 10.1097/01.coc.0000092564.16409.cd | - |
dc.description.citedreference | Sood BM, 2002, INT J GYNECOL CANCER, V12, P459 | - |
dc.description.citedreference | GRIGSBY PW, 2001, INT J RADIAT ONCOL, V49, P7338 | - |
dc.description.citedreference | Peters WA, 2000, J CLIN ONCOL, V18, P1606 | - |
dc.description.citedreference | Sedlis A, 1999, GYNECOL ONCOL, V73, P177 | - |
dc.description.citedreference | Varia MA, 1998, INT J RADIAT ONCOL, V42, P1015 | - |
dc.description.citedreference | Grigsby PW, 1998, INT J RADIAT ONCOL, V41, P817 | - |
dc.description.citedreference | HACKER NF, 1995, INT J GYNECOL CANCER, V5, P250 | - |
dc.description.citedreference | VIGLIOTTI AP, 1992, INT J RADIAT ONCOL, V23, P501 | - |
dc.description.citedreference | MALFETANO JH, 1991, GYNECOL ONCOL, V42, P44 | - |
dc.description.citedreference | STEHMAN FB, 1991, CANCER, V67, P2776 | - |
dc.description.citedreference | DELGADO G, 1990, GYNECOL ONCOL, V38, P352 | - |
dc.description.citedreference | PODCZASKI E, 1990, CANCER, V66, P251 | - |
dc.description.citedreference | DELGADO G, 1989, GYNECOL ONCOL, V35, P314 | - |
dc.description.citedreference | LOVECCHIO JL, 1989, GYNECOL ONCOL, V34, P43 | - |
dc.description.citedreference | GASPAR LE, 1989, RADIOLOGY, V172, P271 | - |
dc.description.citedreference | CRAWFORD JS, 1987, RADIOLOGY, V164, P255 | - |
dc.description.citedreference | NORI D, 1985, INT J RADIAT ONCOL, V11, P1469 | - |
dc.description.citedreference | BERMAN ML, 1984, GYNECOL ONCOL, V19, P8 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.